Compare GSK plc (GSK) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Snap On Incorporated — how do they compare? GSK plc trades at $52.58 (market cap $101.34B), while Snap On Incorporated trades at $411.67 (market cap $20.91B). The key difference: GSK plc is far larger — about 4.8× Snap On Incorporated's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | SNA | |
|---|---|---|
Market Cap | $101.34B | $20.91B |
Sector | Health | Technology |
52-Week High | $61.18 | $413.62 |
52-Week Low | $36.20 | $313.01 |
Enterprise Value | $121.95B | $20.43B |
Dividend Yield | 3.49% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
SNA trades at $411.07, up 1.59% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $407.50. Recent Q1 2026 earnings missed estimates, but revenue grew 5.8% year-over-year, and the company maintains strong profitability with a 19.6% net income margin. Strategic acquisitions like Diesel Laptops for $100 million (Business Wire, June 9, 2026) aim to expand heavy-duty diagnostics capabilities.
The stock offers steady dividend income and share repurchases but faces risks from muted growth projections and margin pressures. Analyst sentiment is predominantly bullish (64.7% buy ratings), though valuation at a P/E of 20.84 may limit upside if earnings growth disappoints. Key catalysts include Q2 2026 results on July 23, 2026, with investors watching for organic sales momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
